Migalastat HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 510224

CAS#: 75172-81-5 (HCl)

Description: Migalastat HCl, also known as AT1001 or GR181413A, is a pharmacological chaperone that selectively binds, stabilizes, and increases cellular levels of α-Gal A. Oral administration of migalastat HCl reduces tissue GL-3 in Fabry transgenic mice, and in urine and kidneys of some FD patients. Migalastat HCl may provide a potential novel genotype-specific treatment for Fabry Disease (FD). Phase 3 studies are ongoing. Fabry disease (FD) is a genetic disorder resulting from deficiency of the lysosomal enzyme α-galactosidase A (α-Gal A) which leads to globotriaosylceramide (GL-3) accumulation in multiple tissues.

Chemical Structure

Migalastat HCl
CAS# 75172-81-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 510224
Name: Migalastat HCl
CAS#: 75172-81-5 (HCl)
Chemical Formula: C6H13NO4
Exact Mass:
Molecular Weight: 163.17
Elemental Analysis: C, 44.16; H, 8.03; N, 8.58; O, 39.22

Size Price Shipping out time Quantity
5mg USD 90 Same day
10mg USD 150 Same day
25mg USD 250 Same day
50mg USD 450 Same day
100mg USD 850 Same day
200mg USD 1550 Same day
Inquire bulk and customized quantity

Pricing updated 2021-03-01. Prices are subject to change without notice.

Migalastat HCl, purity > 98%, is in stock. The same day shipping out after order is received.

Related CAS #: 108147-54-2 (free base)   75172-81-5 (HCl)    

Synonym: AT1001; AT 1001; AT-1001; GR181413A; GR 181413A; GR-181413A; 1,5-Dideoxy-1,5-imino-D-galactitol; 1-Deoxygalactonojirimycin; 1-Deoxygalactostatin; Amigal; Migalastat; Galafold

IUPAC/Chemical Name: (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride.


InChi Code: InChI=1S/C6H13NO4.ClH/c8-2-3-5(10)6(11)4(9)1-7-3;/h3-11H,1-2H2;1H/t3-,4+,5+,6-;/m1./s1

SMILES Code: O[C@H]1[C@@H](CO)NC[C@H](O)[C@H]1O.[H]Cl

Grey to light yellow solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
0 – 4 C for short term (weeks to 1 month) or -20 C for long terms (months to years).

soluble in DMSO, soluble in water.

Shelf Life:
>2 years if stored properly.

Drug Formulation:
PBS buffer, water, etc.

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Preparing Stock Solutions

The following data is based on the product molecular weight 163.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548736/ PubMed PMID: 31644045.

2: McCafferty EH, Scott LJ. Migalastat: A Review in Fabry Disease. Drugs. 2019 Apr;79(5):543-554. doi: 10.1007/s40265-019-01090-4. Review. Erratum in: Drugs. 2019 Jul 10;:. PubMed PMID: 30875019; PubMed Central PMCID: PMC6647464.

3: Migalastat for Fabry disease. Aust Prescr. 2019 Feb;42(1):36-37. doi: 10.18773/austprescr.2018.073. Epub 2018 Dec 13. Review. PubMed PMID: 30765910; PubMed Central PMCID: PMC6370600.

4: Pharmacoeconomic Review Report: Migalastat (Galafold): (Amicus Therapeutics): Indication: Fabry Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533451/ PubMed PMID: 30457791.

5: CADTH Canadian Drug Expert Committee Recommendation: Migalastat (Galafold — Amicus Therapeutics): Indication: Fabry Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533471/ PubMed PMID: 30457790.

6: Clinical Review Report: Migalastat (Galafold): (Amicus Therapeutics): Indication: Fabry Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533676/ PubMed PMID: 30457788.

7: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK532501/ PubMed PMID: 30372005.

Additional Information